RPL19P11

Across TCGA pan-cancer cohorts, RPL19P11 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RPL19P11’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL19P11 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL19P11 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

KIRC, COAD, and KICH are the cancer types where RPL19P11 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL19P11 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.209	<.001	5	view →
COAD	All	All	+0.146	.008	4	view →
KICH	Female	All	−0.131	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

RPL19P11–KIRC

Open the KIRC breakdown →